Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline 0.9% Clear all
Not listed Phase 2 Interventional

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

NCT03840057
View directory record Official record
Conditions
Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions
Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%
Drug
Lead sponsor
Waihong Chung
Other
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Postpartum Family Planning

NCT03844633
View directory record Official record
Conditions
Delay in Time to Lactogenesis Stage II
Interventions
Depo-Provera Injectable Product, Placebos
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pertussis Vaccine in Healthy Pregnant Women

NCT00707148
View directory record Official record
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
4
States / cities
Durham, North Carolina • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 3 Interventional

Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart

NCT00335335
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
iodixanol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT02020889
View directory record Official record
Conditions
Churg-Strauss Syndrome
Interventions
Mepolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Denver, Colorado • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

The Bladder Instillation Comparison Study

NCT02695771
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Mitomycin C, Gemcitabine
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 23, 2026, 5:55 AM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

NCT07214311
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
PLG0206, Placebo
Drug
Lead sponsor
Peptilogics
Industry
Eligibility
18 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Sarasota, Florida • Tamarac, Florida • Shreveport, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 3 Interventional Results available

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

NCT00316004
View directory record Official record
Conditions
Brain Injuries, Traumatic
Interventions
7.5% Hypertonic Saline in 6% Dextran-70 (HSD), 7.5% Hypertonic Saline (HS), 0.9% Normal Saline (NS)
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Not applicable Interventional Results available

Interscalene Nerve Blocks With Ropivacaine Alone, With Dexamethasone, Plus Systemic Dexamethasone

NCT00519584
View directory record Official record
Conditions
Pain
Interventions
Ropivacaine, dex, Bupivacaine, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Cleveland, Ohio • Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 5:55 AM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

NCT07384052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

NCT02058290
View directory record Official record
Conditions
Bowel Obstruction
Interventions
IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 23, 2026, 5:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403
View directory record Official record
Conditions
Healthy
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

NCT03608397
View directory record Official record
Conditions
Cervical Dystonia
Interventions
DaxibotulinumtoxinA for injection, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02694978
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, FCM
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
100
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 23, 2026, 5:55 AM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional

Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

NCT00137332
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-486 (ZP-123), 0.9% Sodium Chloride, USP
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
19
States / cities
Sacramento, California • San Francisco, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 23, 2026, 5:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cidofovir in Renal Transplant Recipients With BKVN

NCT00138424
View directory record Official record
Conditions
BK Virus (Nephropathy)
Interventions
Cidofovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 23, 2026, 5:55 AM EDT
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 23, 2026, 5:55 AM EDT